Actively Recruiting
Phase 3 Open-label Study of Radotinib for Chronic Phase Ph Chronic Myeloid Leukemia Patients with Prior TKI Treatment Failure or Intolerance
Led by Il-Yang Pharm. Co., Ltd. · Updated on 2026-09-03
173
Participants Needed
18
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multinational, multicenter, open-label Phase III study to evaluate the efficacy and safety of Radotinib in adults with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia CP-CML who have experienced failure or intolerance to prior tyrosine kinase inhibitor TKI therapies, including Imatinib. This study aims to understand how Radotinib performs in this patient population where previous treatments have not been successful or tolerated. Participants will receive Radotinib 400 mg orally twice daily for 12 months. Dose adjustments to 600 mg or 400 mg twice daily are permitted if participants experience hematologic or non-hematologic toxicities that resolve within specified time frames. This is a single-arm study with no placebo or comparator group, involving continuous administration of the study drug throughout the treatment period. During the study, participants will be regularly monitored for responses such as major cytogenetic response at 6 months and other outcomes including complete cytogenetic response, major molecular response, overall survival, and progression-free survival up to 24 months. Safety and tolerability will also be assessed. The study enrollment started in 2018 and is expected to complete by mid-2028, with ongoing follow-up to assess long-term outcomes.
CONDITIONS
Brief Title
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Research Team
N
Na Yun Kim
K
Kang Hi An
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here